Princess Margaret Cancer Centre - UHN
The Kridel lab is seeking a talented postdoctoral fellow to lead ongoing efforts to enhance our understanding of lymphoma pathogenesis by leveraging large datasets. The research will focus on either of the following topics: (i) dissection of immune correlates underlying both common and rare lymphoma types using single cell sequencing; (ii) development of liquid biopsy-based biomarkers for the accurate classification and monitoring of lymphoma. The post-doctoral fellow will design and carry out experiments to address key questions in the above topics and lead the writing of scientific manuscripts. The successful candidate will be embedded in a rich scientific environment that provides ample opportunities for development of technical, as well as leadership skills. Highly motivated individuals with a desire to make an impact in the field of cancer genomics are encouraged to apply.
- analysis of single-nuclei sequencing or circulating tumour DNA data
- critical analysis of results in light of the ambient literature
- liaising with internal and external collaborators
- summarizing project output for presentations at lab meetings, as well as for external dissemination
- manuscript writing
- independent thinking and involvement in the design of future research projects will be strongly encouraged
- PhD degree in bioinformatics, computer science, statistics or molecular biology
- experience with cancer genomics is required
- excellent communication skills
- willingness to work in a team environment
Our research is driven by the observation that the outcomes of lymphoma patients are extremely variable. Certain patients are seemingly cured, or enjoy very long remissions, while other patients experience disease relapse or refractoriness. By and large, we are currently unable to offer treatment that targets the therapeutic vulnerabilities that underlie a given patient’s lymphoma. We would like to change this. We postulate that the comprehensive deciphering of the biological underpinnings of lymphoma will lead to improved therapies for lymphoma patients. In order to achieve this goal, we are applying state-of-the-art genomic techniques to primary patient samples to unravel tumour heterogeneity and to develop novel, innovative biomarkers to predict outcome in lymphoma. Furthermore, we are leveraging novel findings from discovery platforms to elucidate mechanisms of lymphoma pathogenesis, tumour evolution and treatment resistance. Our ultimate goal is to improve patient outcomes through a better understanding of the diversity of responses to treatment and by tailoring therapy to each individual patient. See our lab website for further information: https://kridel-lab.ca/.
The Princess Margaret Cancer Centre (PMCC) is one of the top 5 cancer centres in the world. PMCC is a teaching hospital within the University Health Network and affiliated with the University of Toronto, with the largest cancer research program in Canada. This rich working environment provides ample opportunities for collaboration and scientific exchange with a large community of clinical, genomics, computational biology and machine learning groups at the University of Toronto and associated institutions, such as the Ontario Institute of Cancer Research, Hospital for Sick Children and Donnelly Centre.